You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR ENCORAFENIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for encorafenib

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01777776 ↗	Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.	Terminated	Array BioPharma	Phase 1/Phase 2	2013-07-01	To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
NCT01820364 ↗	LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma	Terminated	Array BioPharma	Phase 2	2013-11-01	The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
NCT02109653 ↗	Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC	Withdrawn	Array BioPharma	Phase 2	2015-06-01	This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
NCT02109653 ↗	Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC	Withdrawn	Array Biopharma, now a wholly owned subsidiary of Pfizer	Phase 2	2015-06-01	This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for encorafenib

Condition Name

Chart
Table

Condition Name for encorafenib
Intervention	Trials
Melanoma	12
Metastatic Melanoma	8
Metastatic Colorectal Cancer	7
Colorectal Cancer	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for encorafenib
Intervention	Trials
Melanoma	28
Colorectal Neoplasms	18
Brain Neoplasms	7
Neoplasms	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for encorafenib

Trials by Country

Map
Table

Trials by Country for encorafenib
Location	Trials
United States	178
China	41
Italy	35
Spain	30
Germany	28
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for encorafenib
Location	Trials
Texas	15
California	15
Tennessee	11
New York	11
Florida	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for encorafenib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for encorafenib
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	6
Phase 2/Phase 3	1
[disabled in preview]	34
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for encorafenib
Clinical Trial Phase	Trials
Recruiting	37
Not yet recruiting	19
Active, not recruiting	6
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for encorafenib

Sponsor Name

Chart
Table

Sponsor Name for encorafenib
Sponsor	Trials
Pfizer	20
National Cancer Institute (NCI)	14
Array BioPharma	13
[disabled in preview]	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for encorafenib
Sponsor	Trials
Industry	81
Other	54
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.